ストックスクリーナーアプリを入手
2.72
2.86%
-0.08
アフターアワーズ：
2.78
0.06
+2.21%
Editas Medicine Inc (EDIT) 最新ニュース
Editas Medicine (NASDAQ:EDIT) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
Editas Medicine Inc. Moves Into Overbought Range Analysts CautiousPrice Action & Stepwise Swing Trade Plans - beatles.ru
Editas Medicine (NASDAQ:EDIT) Issues Quarterly Earnings Results - MarketBeat
Editas Medicine (NASDAQ:EDIT) Price Target Raised to $6.00 at Robert W. Baird - MarketBeat
Short interest data insights for Editas Medicine Inc.2025 Market Trends & Low Risk High Win Rate Stock Picks - Newser
Intraday pattern recognizer results for Editas Medicine Inc.July 2025 Sector Moves & Weekly Chart Analysis and Trade Guides - Newser
How to recover losses in Editas Medicine Inc. stockPortfolio Growth Summary & Low Drawdown Trading Techniques - Newser
Ranking Editas Medicine Inc. among high performing stocks via toolsJuly 2025 Technicals & Fast Moving Trade Plans - Newser
How to build a custom watchlist for Editas Medicine Inc.Weekly Risk Summary & Fast Exit/Entry Strategy Plans - Newser
Trend analysis for Editas Medicine Inc. this weekWeekly Trend Recap & Comprehensive Market Scan Insights - Newser
Editas Medicine Inc. Faces Significant Business Risks: Key Factors for Investors to Watch - MSN
What makes Editas Medicine Inc. stock price move sharplyTrend Reversal & High Accuracy Buy Signal Tips - Newser
Is Editas Medicine Inc. showing signs of accumulationMarket Growth Review & High Accuracy Buy Signal Tips - Newser
HC Wainwright Boosts Editas Medicine Price Target to $5.00, Analysts Predict 22.47% Upside - AInvest
Editas Medicine's Q2 Earnings Boost Stock Price 34% Amid Plans to Nominate First In Vivo Development Candidate in September - AInvest
Editas Medicine (NASDAQ:EDIT) Downgraded to Sell Rating by Wall Street Zen - Defense World
Why Editas Medicine Inc. stock attracts strong analyst attentionJuly 2025 Pullbacks & Free Verified High Yield Trade Plans - sundaytimes.kr
Editas Medicine: Strategic Position Balances Cautious Development and Financial Stability - TipRanks
What drives Editas Medicine Inc.’s stock priceProduct Launch & Daily Technical Stock Forecast Reports - thegnnews.com
Why Editas Medicine Stock Was Skyrocketing This Week - AOL.com
H.C. Wainwright raises Editas Medicine stock price target to $5 on pipeline progress - Investing.com Canada
Editas Medicine: HC Wainwright Raises PT to $5, Maintains Buy Rating - AInvest
Robert W. Baird Forecasts Strong Price Appreciation for Editas Medicine (NASDAQ:EDIT) Stock - Defense World
How Interest Rate Changes Impact Editas Medicine Inc. Stock PerformanceMarket Movement Recap & Daily Profit Focused Stock Screening - Newser
Editas Medicine Inc. Rebound Backed by Sentiment Shift2025 Price Action Summary & Consistent Income Trade Recommendations - sundaytimes.kr
Applications Of Genetic Engineering Market is Booming Worldwide | Editas Medicine , Intellia Therapeutics - newstrail.com
Editas Medicine Inc. Pullback Analyzed — Is It Time to Exit2025 Sector Review & Weekly Chart Analysis and Trade Guides - sundaytimes.kr
Editas Medicine Reports Q2 2025 Progress and Financials - TipRanks
Editas Medicine’s SWOT analysis: gene editing stock faces challenges, opportunities - Investing.com
A Quick Look at Today's Ratings for Editas Medicine(EDIT.US), With a Forecast Between $3 to $6 - 富途牛牛
Editas Medicine shares surge 28.87% intraday after strong Q2 earnings and positive analyst ratings. - AInvest
Editas Medicine Surges 34% on Q2 Momentum and Strategic Milestones – What’s Fueling the Biotech Rally? - AInvest
Can Editas Medicine Inc. Regain Momentum After BreakdownQuarterly Profit Review & Precise Buy Zone Identification - 선데이타임즈
Baird raises Editas Medicine stock price target to $6 on pipeline progress - Investing.com Nigeria
Editas: Q2 Earnings Snapshot - Greenwich Time
Editas Medicine (EDIT) Reports Q2 Loss, Tops Revenue Estimates - MSN
What high frequency data says about Editas Medicine Inc.2025 Bull vs Bear & Risk Controlled Stock Pick Alerts - Newser
Editas Medicine 2025 Q2 Earnings Narrows Losses Amid Revenue Surge - AInvest
Editas Medicine Announces Second Quarter 2025 Results and Business Updates - GlobeNewswire
Editas Medicine's Q2 Performance: Assessing Progress Amid Financial Challenges - AInvest
Editas Medicine Misses Expectations But Stays Focused On The Future - Finimize
Editas Medicine earnings missed by $0.23, revenue topped estimates - Investing.com Canada
Editas Medicine Inc Q2 2025 Earnings: Revenue Soars to $3.6M, Beating Estimates; EPS Misses at -$0.63 - GuruFocus
Editas Medicine posts Q2 net loss of $53.2 mln - MarketScreener
Editas Medicine Q2 2025: On track to file IND by mid-2026, proof-of-concept by year-end. - AInvest
Editas Medicine Reports Q2 2025 Results, Advances Gene Editing Programs - AInvest
Editas Medicine narrows losses as Bristol Myers Squibb partnership hits key milestone - Stock Titan
1.38%
0.27%
大文字化:
|
ボリューム (24 時間):